The ALK gene, an attractive target for inhibitor development

Current Topics in Medicinal Chemistry

Volumn 11, Issue 11, 2011, Pages 1406-1419

  Tartari, Carmen J ^a   Scapozza, Leonardo ^b   Gambacorti Passerini, Carlo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Anaplastic Lymphoma kinase (ALK); Modeling; Molecular targeting; Oncogenic fusion protein; Small molecule inhibitors; Targeted cancer therapy; Tyrosine kinase

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [(30 BROMO 40 HYDROXYPHENYL)AMINO] 6,7 DIMETHOXYQUINAZOLINE; 5 ARYL PYRIDONE 3 CARBOXAMIDE; 5 CHLORO 2,4 DIAMINOPHENYLPYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; CEP 14083; CEP 14513; CRIZOTINIB; DASATINIB; ERLOTINIB; GEFITINIB; GELDANAMYCIN; HERBIMYCIN A; HYBRID PROTEIN; IMATINIB; JANUS KINASE; NMS 628; NVP TAE 684; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RAPAMYCIN; SORAFENIB; STAT PROTEIN; STAUROSPORINE; SUNITINIB; UNCLASSIFIED DRUG; WHI P 154; WZ 5 126;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHEMICAL STRUCTURE; CHROMOSOME REARRANGEMENT; CRYSTAL STRUCTURE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EWING SARCOMA; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENE TARGETING; GLIOBLASTOMA; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MELANOMA; NEUROBLASTOMA; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN VARIANT; RETINOBLASTOMA; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79958117804     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795589593     Document Type: Article

References (135)

1. Morris, S.W.; Kirstein, M.N.; Valentine, M.B.; Dittmer, K.G.; Shapiro, D.N.; Saltman, D.L.; Look, A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 1994, 263, 1281-4.
2. Morris, S.W.; Naeve, C.; Mathew, P.; James, P.L.; Kirstein, M.N.; Cui, X.; Witte, D.P. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene, 1997, 14, 2175-2188.
3. Iwahara, T.; Fujimoto, J.; Wen, D.; Cupples, R.; Bucay, N.; Arakawa, T.; Mori, S.; Ratzkin, B.; Yamamoto, T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene, 1997, 14, 439-449.
4. Pulford, K.; Morris, S.W.; Turturro, F. Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell Physiol., 2004, 199, 330-358.
5. Pulford, K.; Lamant, L.; Espinos, E.; Jiang, Q.; Xue, L.; Turturro, F.; Delsol, G.; Morris, S.W. The emerging normal and diseaserelated roles of anaplastic lymphoma kinase. Cell Mol. Life Sci., 2004, 61, 2939-2953.
6. Cheuk, W.; Chan, J.K. Timely topic, anaplastic lymphoma kinase (ALK) spreads its influence. Pathology, 2001, 33, 7-12.
7. Coluccia, A.M.; Gunby, R. H.; Tartari, C.J.; Scapozza, L.; Gambacorti-Passerini, C.; Passoni, L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Exp. Opin. Ther. Targets. 2005, 9, 515-532.
8. Stoica, G. E.; Kuo, A.; Aigner, A.; Sunitha, I.; Souttou, B.; Malerczyk, C.; Caughey, D. J.; Wen, D.; Karavanov, A.; Riegel, A.T.; Wellstein, A. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem., 2001, 276, 16772-16779.
9. Vernersson, E.; Khoo, N.K.; Henriksson, M.L.; Roos, G.; Palmer, R.H.; Hallberg, B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns, 2006, 6, 448-461.
10. Pulford, K.; Lamant, L.; Morris, S.W.; Butler, L.H.; Wood, K.M.; Stroud, D.; Delsol, G.; Mason, D.Y. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood, 1997, 89, 1394-1404.
11. Webb, T.R.; Slavish, J.; George, R.E.; Look, A.T.; Xue, L.; Jiang, Q.; Cui, X.; Rentrop, W.B.; Morris, S.W. Anaplastic lymphoma kinase, role in cancer pathogenesis and small-molecule inhibitor development for therapy. Exp. Rev. Anticancer Ther., 2009, 9, 331-356.
12. Stoica, G. E.; Kuo, A.; Powers, C.; Bowden, E.T.; Sale, E. B.; Riegel, A.T.; Wellstein, A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem., 2002, 277, 35990-35998.
13. Loren, C.E.; Englund, C.; Grabbe, C.; Hallberg, B.; Hunter, T.; Palmer, R.H. A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster. EMBO Rep., 2003, 4, 781-786.
14. Loren, C.E.; Scully, A.; Grabbe, C.; Edeen, P.T.; Thomas, J.; McKeown, M.; Hunter, T.; Palmer, R.H. Identification and characterization of DAlk, a novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells, 2001, 6, 531-544.
15. Lu, K. V.; Jong, K.A.; Kim, G.Y.; Singh, J.; Dia, E.Q.; Yoshimoto, K.; Wang, M.Y.; Cloughesy, T.F.; Nelson, S.F.; Mischel, P.S. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem., 2005, 280, 26953-26964.
16. Dirks, W.G.; Fahnrich, S.; Lis, Y.; Becker, E.; MacLeod, R.A.; Drexler, H.G. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int. J. Cancer, 2002, 100, 49-56.
17. Powers, C.; Aigner, A.; Stoica, G.E.; McDonnell, K.; Wellstein, A. Pleiotrophin signaling through anaplastic lymphoma kinase is ratelimiting for glioblastoma growth. J. Biol. Chem., 2002, 277, 14153-14158.
18. Lamant, L.; Pulford, K.; Bischof, D.; Morris, S.W.; Mason, D.Y.; Delsol, G.; Mariame, B. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol., 2000, 156, 1711-1721.
19. Osajima-Hakomori, Y.; Miyake, I.; Ohira, M.; Nakagawara, A.; Nakagawa, A.; Sakai, R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol., 2005, 167,213-222.
20. Zoubek A.; Simonitsch I.; Panzer-Grumayer ER.; Ghali D.; Pfleiderer C.; Haas OA.; Mann G.; Lang S.; Radaszkiewicz T.; Gadner H. Ewing tumor after treatment of Ki-1+ anaplastic large cell lymphoma. Therapy-associated secondary neoplasm or unrelated coincidence? Cancer Genet Cytogenet, 1995, 83, 5-11.
21. Rassidakis, G. Z.; Lai, R.; Herling, M.; Cromwell, C.; Schmitt-Graeff, A.; Medeiros, L.J. Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma. Am. J. Pathol., 2004, 164, 2259-2267.
22. Czubayko, F.; Schulte, A. M.; Berchem, G.J.; Wellstein, A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc. Natl. Acad. Sci. USA, 1996, 93, 14753-14758.
23. Subramaniam, M.M.; Piqueras, M.; Navarro, S.; Noguera, R. Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas. Hum Pathol., 2009, 40, 1638-1642.
24. Brodeur, G. M. Neuroblastoma, biological insights into a clinical enigma. Nat. Rev. Cancer, 2003, 3, 203-216.
25. Miyake, I.; Hakomori, Y.; Shinohara, A.; Gamou, T.; Saito, M.; Iwamatsu, A.; Sakai, R. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene, 2002, 21, 5823-5834.
26. Pelicci, G.; Dente, L.; De Giuseppe, A.; Verducci-Galletti, B.; Giuli, S.; Mele, S.; Vetriani, C.; Giorgio, M.; Pandolfi, P.P.; Cesareni, G.; Pelicci, P. G. A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. Oncogene, 1996, 13, 633-641.
27. Palmer, R.H.; Vernersson, E.; Grabbe, C.; Hallberg, B. Anaplastic lymphoma kinase, signalling in development and disease. Biochem. J., 2009, 420, 345-361.
28. George, R.E.; Sanda, T.; Hanna, M.; Frohling, S.; Luther, W2nd.; Zhang, J.; Ahn, Y.; Zhou, W.; London, W.B.; McGrady, P.; Xue, L.; Zozulya, S.; Gregor, V.E.; Webb, T.R.; Gray, N.S.; Gilliland, D.G.; Diller, L.; Greulich, H.; Morris, S.W.; Meyerson, M.; Look, A.T. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature, 2008, 455, 975-978.
29. Pulford, K.; Morris, S.W.; Mason, D.Y. Anaplastic lymphoma kinase proteins and malignancy. Curr. Opin. Hematol., 2001, 8, 231-236.
30. Kadin, M.E.; Morris, S. W. The t(2;5) in human lymphomas. Leuk Lymphoma, 1998, 29, 249-256.
31. Falini, B.; Bigerna, B.; Fizzotti, M.; Pulford, K.; Pileri, S.A.; Delsol, G.; Carbone, A.; Paulli, M.; Magrini, U.; Menestrina, F.; Giardini, R.; Pilotti, S.; Mezzelani, A.; Ugolini, B.; Billi, M.; Pucciarini, A.; Pacini, R.; Pelicci, P. G.; Flenghi, L. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am. J. Pathol., 1998, 153, 875-886.
32. Jager, R.; Hahne, J.; Jacob, A.; Egert, A.; Schenkel, J.; Wernert, N.; Schorle, H.; Wellmann, A. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res., 2005, 25, 3191-3196.
33. Colleoni, G.W.; Bridge, J.A.; Garicochea, B.; Liu, J.; Filippa, DA.; Ladanyi, M. ATIC-ALK, a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion. inv (2)(p23q35). Am. j. Pathol. 2000, 156, 781-789.
34. Trinei, M.; Lanfrancone, L.; Campo, E.; Pulford, K.; Mason, D.; Pelicci, P.; Falini, B. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res., 2000, 60, 793-793.
35. Ma, Z.; Cools, J.; Marynen, P.; Cui, X.; Siebert, R.; Gesk, S.; Schlegelberger, B.; Peeters, B.; De Wolf-Peeters, C.; Wlodarska, I.; Morris, S. W. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood, 2000, 95, 2144-2149.
36. Liang, X.; Meech, S. J.; Odom, L. F.; Bitter, M. A.; Ryder, J. W.; Hunger, S. P.; Lovell, M. A.; Meltesen L.; Wei, Q.; Williams, S. A.; Hutchinson, R. N.; Mc Gavran, L. Assessment of t(2, 5)(p23, q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am. J. Clin. Pathol., 2004, 121, 496-506.
37. Cools, J.; Wlodarska, I.; Somers, R.; Mentens, N.; Pedeutour, F.; Maes, B.; De Wolf-Peeters, C.; Pauwels, P.; Hagemeijer, A.; Marynen, P. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase. In anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Gen. Chrom. Cancer. 2002, 34, 354-362.
38. Debelenko, L.V.; Arthur, D. C.; Pack, S. D.; Helman, L. J.; Schrump, D. S.; Tsokos, M. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab. Invest., 2003, 83, 1255-1265.
39. Touriol, C.; Greenland C.; Lamant, L.; Pulford K.; Bernard, F.; Rousset, T.; Mason, D. Y.; Delsol, G. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma, 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood, 2000, 95, 3204-3207.
40. Gascoyne, R. D.; Lamant, L.; Martin-Subero, J. I.; Lestou, V. S.; Harris, N. L.; Muller-Hermelink, H. K.; Seymour, J. F.; Campbell, L. J.; Horsman, D. E.; Auvigne, I.; Espinos, E.; Siebert, R.; Delsol. G. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements, report of 6 cases. Blood, 2003, 102, 2568-2573.
41. Tort, F.; Pinyol, M.; Pulford. K.; Roncador, G.; Hernandez, L.; Nayach, I.; Kluin-Nelemans, H. C.; Kluin P.; Touriol, C.; Delsol, G.; Mason, D.; Campo, E. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab. Invest., 2001, 81, 419-426.
42. Tort, F.; Campo, E.; Pohlman, B.; His, E. Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Hum. Pathol., 2004, 35, 1038-1041.
43. Hernandez, L.; Pinyol, M.; Hernandez, S.; Bea, S.; Pulford, K.; Rosenwald, A.; Lamant, L.; Falini, B.; Ott, G.; Mason, D.Y.; Delsol, G.; Campo, E. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood, 1999, 94, 3265-3268.
44. Hernandez, L.; Bea, S.; Bellosillo, B.; Pinyol M.; Falini, B.; Carbone, A.; Ott, G.; Rosenwald, A.; Fernandez, A.; Pulford, K.; Mason, D.; Morris, S. W.; Santos, E.; Campo, E. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas, identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am. J. Pathol., 2002, 160, 1487-1494.
45. Rosenwald, A.; Ott, G.; Pulford, K.; Katzenberger, T.; Kuhl, J.; Kalla, J.; Ott, M. M.; Mason, D. Y.; Muller-Hermelink, H. K. t(1;2)(q21;p23) and T(2;3)(p23;q21), two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood, 1999, 94, 362-364.
46. Lamant, L.; Dastugue, N.; Pulford, K.; Delsol, G.; Mariame, B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood, 1999, 93, 3088-3095.
47. Meech, S. J.; McGavran, L.; Odom, L. F.; Liang, X.; Meltesen, L.; Gump, J.; Wei, Q.; Carlsen, S.; Hunger, S. P. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion. Blood, 2001, 98, 1209-1216.
48. Ma, Z.; Hill, D. A.; Collins, M. H.; Morris, S. W.; Sumegi, J.; Zhou, M.; Zuppan, C.; Bridge, J. A. Fusion of ALK to the Ranbinding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chrom. Cancer. 2003, 37, 98-105.
49. Panagopoulos, I.; Nilsson, T.; Domanski, H. A.; Isaksson, M.; Lindblom, P.; Mertens, F.; Mandahl, N. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int. J. Cancer. 2006, 118, 1181-1186.
50. Martelli, MP.; Sozzi, G.; Hernandez, L.; Pettirossi, V.; Navarro, A.; Conte, D.; Gasparini, P.; Perrone, F.; Modena, P.; Pastorino, U.; Carbone, A.; Fabbri, A.; Sidoni, A.; Nakamura, S.; Gambacorta, M.; Fernandez, P. L.; Ramirez. J.; Chan. J.K.; Grigioni, W. F.; Campo. E.; Pileri, S.A.; Falini. B. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol., 2009, 174, 661-70.
51. Soda, M.; Takada, S.; Takeuchi, K.; Choi, YL.; Enomoto, M.; Ueno, T.; Haruta, H.; Hamada, T.; Yamashita, Y.; Ishikawa, Y.; Sugiyama, Y.; Mano, H. A mouse model for EML4-ALK-positive lung cancer. Proc. Natl. Acad. Sci. U S A. 2008, 105,19893-19897.
52. Takeuchi, K.; Choi, Y. L.; Togashi, Y.; Soda, M.; Hatano, S.; Inamura, K.; Takada, S.; Ueno, T.; Yamashita, Y.; Satoh, Y.; Okumura, S.; Nakagawa K.; Ishikawa, Y.; Mano, H. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistrybased diagnostic system for ALK-positive lung cancer. Clin. Cancer Res., 2009, 15, 3143-3149.
53. Kutok, J. L.; Aster, J.C. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J. Clin. Oncol., 2002, 20, 3691-3702.
54. Mason, D. Y.; Bastard, C.; Rimokh, R.; Dastugue, N.; Huret, J. L.; Kristoffersson, U.; Magaud, J. P.; Nezelof, C.; Tilly, H.; Vannier, J. P. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br. J. Haematol., 1990, 74, 161-168.
55. Mason, D.Y.; Pulford, K. A.; Bischof, D.; Kuefer, M. U.; Butler, L. H.; Lamant, L.; Delsol, G.; Morris, S, W. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res., 1998, 58, 1057-1062.
56. Bischof, D.; Pulford, K.; Mason, D. Y.; Morris, S. W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphomaassociated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell Biol., 1997, 17, 2312-2325.
57. Fujimoto, J.; Shiota, M.; Iwahara, T.; Seki, N.; Satoh, H.; Mori, S.; Yamamoto, T. Characterization of the transforming activity of p80; a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl. Acad. Sci. USA, 1996, 93, 4181-4186.
58. Chiarle, R.; Gong, J. Z.; Guasparri, I.; Pesci, A.; Cai, J.; Liu, J.; Simmons, W. J.; Dhall, G.; Howes, J.; Piva, R.; Inghirami, G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 2003, 101, 1919-1927.
59. Kuefer, M. U.; Look, A. T.; Pulford, K.; Behm, F. G.; Pattengale P. K.; Mason, D. Y.; Morris, S. W. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood, 1997, 90, 2901-2910.
60. Lange, K.; Uckert, W.; Blankenstein, T.; Nadrowitz, R.; Bittner, C.; Renauld, J. C.; van Snick, J.; Feller, A. C.; Merz, H. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene, 2003, 22, 517-5127.
61. De Paepe, P.; Baens, M.; van Krieken, H.; Verhasselt, B.; Stul, M.; Simons, A.; Poppe, B.; Laureys, G.; Brons, P.; Vandenberghe, P.; Speleman, F.; Praet, M.; De Wolf-Peeters, C.; Marynen, P.; Wlodarska, I. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood, 2003, 102, 2638-2641.
62. Onciu, M.; Behm, F. G.; Downing, J. R.; Shurtleff, S. A.; Raimondi, S. C.; Ma, Z.; Morris, S. W.; Kennedy, W.; Jones, S. C.; Sandlund, J. T. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript, report of 2 cases. Blood, 2003, 102, 2642-2644.
63. Adam, P.; Katzenberger, T.; Seeberger, H.; Gattenlohner, S.; Wolf, J.; Steinlein, C.; Schmid, M.; Muller-Hermelink, H. K.; Ott, G. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am. J. Surg. Pathol., 2003, 27, 1473-1476.
64. Chikatsu, N.; Kojima, H.; Suzukawa, K.; Shinagawa, A.; Nagasawa, T.; Ozawa, H.; Yamashita, Y.; Mori, N. ALK+.; CD30-; CD20-large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod. Pathol., 2003, 16, 828-832.
65. Bai, R. Y.; Dieter, P.; Peschel, C.; Morris, S. W.; Duyster, J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol. Cell. Biol., 1998, 18, 6951-6961.
66. Turturro, F.; Arnold, M. D.; Frist, A. Y.; Pulford, K. Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin, Cancer Res., 2002, 8, 240-245.
67. Ergin, M.; Denning, M. F.; Izban, K. F.; Amin, H. M.; Martinez, R. L.; Saeed, S.; Alkan, S. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp. Hematol., 2001, 29, 1082-1090.
68. Zhang, Q.; Raghunath, P. N.; Xue, L.; Majewski, M.; Carpentieri, D. F.; Odum, N.; Morris, S.; Skorski, T.; Wasik, M. A. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinasepositive T/null-cell lymphoma. J. Immunol., 2002, 168, 466-474.
69. Zamo, A.; Chiarle, R.; Piva, R.; Howes, J.; Fan, Y.; Chilosi, M.; Levy, D. E.; Inghirami, G. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene, 2002, 21, 1038-1047.
70. Slupianek, A.; Nieborowska-Skorska, M.; Hoser, G.; Morrione, A.; Majewski, M.; Xue, L.; Morris, S. W.; Wasik, M. A.; Skorski, T. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/ anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res., 2001, 61, 2194-2199.
71. Nieborowska-Skorska, M.; Slupianek, A.; Xue, L.; Zhang, Q.; Raghunath, P. N.; Hoser, G.; Wasik, M. A.; Morris, S. W.; Skorski, T. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res., 2001, 61, 6517-6523.
72. Bai, R. Y.; Ouyang, T.; Miething, C.; Morris, S. W.; Peschel, C.; Duyster, J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood, 2000, 96, 4319-4327.
73. Wlodarska, I.; De Wolf-Peeters, C.; Falini, B.; Verhoef, G.; Morris, S. W.; Hagemeijer, A.; Van den Berghe, H. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALKpositive anaplastic large-cell lymphoma. Blood, 1998, 92, 2688-2695.
74. Siebert, R.; Gesk, S.; Harder, L.; Steinemann, D.; Grote, W.; Schlegelberger, B.; Tiemann, M.; Wlodarska, I.; Schemmel, V. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. Blood, 1999, 94, 3614-3617.
75. Greco, A.; Mariani, C.; Miranda, C.; Lupas, A.; Pagliardini, S.; Pomati, M.; Pierotti, M. A. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol, Cell Biol., 1995, 15, 6118-6127.
76. Greco, A.; Fusetti, L.; Miranda, C.; Villa, R.; Zanotti, S.; Pagliardini, S.; Pierotti, M. A. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRKT3 oncogene. Oncogene. 1998, 16, 809-816.
77. Mahajan, R.; Delphin, C.; Guan, T.; Gerace, L.; Melchior, F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell. 1997, 88, 97-107.
78. Tang, B. L.; Zhang, T.; Low, D. Y.; Wong, E. T.; Horstmann, H.; Hong, W. Mammalian homologues of yeast sec31p. An ubiquitously expressed form is localized to endoplasmic reticulum (ER) exit sites and is essential for ER-Golgi transport. J. Biol. Chem., 2000, 275, 13597-13604.
79. Shugrue, C. A.; Kolen, E. R.; Peters, H.; Czernik, A.; Kaiser, C.; Matovcik, L.; Hubbard, A. L.; Gorelick, F. Identification of the putative mammalian orthologue of Sec31P.; a component of the COPII coat. J. Cell. Sci., 1999, 112 (Pt 24), 4547-4556.
80. Drexler, H. G.; Gignac, S.M.; von Wasielewski, R.; Werner, M.; Dirks, W. G. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia., 2000, 14, 1533-1559.
81. Cessna, M. H.; Zhou, H.; Sanger, W. G.; Perkins, S. L.; Tripp, S.; Pickering, D.; Daines, C.; Coffin, C. M. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics, a study of 135 cases. Mod. Pathol., 2002, 15, 931-938.
82. Delsol, G.; Lamant, L.; Mariame, B.; Pulford, K.; Dastugue, N.; Brousset, P.; Rigal-Huguet, F.; al Saati, T.; Cerretti, D.P.; Morris, S.W.; Mason, D. Y. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood, 1997, 89, 1483-1490.
83. Choi Y. L.; Takeuchi, K.; Soda, M.; Inamura, K.; Togashi, Y.; Hatano, S.; Enomoto, M.; Hamada, T.; Haruta, H.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Ueno, T.; Takada, S.; Yamashita, Y.; Sugiyama, Y.; Ishikawa, Y.; Mano, H. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res., 2008, 68, 4971-4976.
84. Rimokh, R.; Magaud, J. P.; Berger, F.; Samarut, J.; Coiffier, B.; Germain, D.; Mason, D. Y. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). Br. J. Haematol., 1989, 71, 31-36.
85. Kaneko, Y.; Frizzera, G.; Edamura, S.; Maseki, N.; Sakurai, M.; Komada, Y.; Tanaka, H.; Sasaki, M.; Suchi, T. A novel translocation, t(2, 5)(p23, q35), in childhood phagocytic large Tcell lymphoma mimicking malignant histiocytosis. Blood, 1989,73, 806-13.
86. Shiota, M.; Fujimoto, J.; Semba, T.; Satoh, H.; Yamamoto, T.; Mori, S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line. AMS3. Oncogene, 1994,9, 1567-1574.
87. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood, 1997, 89, 3909-3918.
88. Harris, N. L.; Jaffe, E. S.; Stein, H.; Banks, P. M.; Chan, J. K.; Cleary, M. L.; Delsol, G.; De Wolf-Peeters, C.; Falini, B.; Gatter, K. C. A revised European-American classification of lymphoid neoplasms, a proposal from the International Lymphoma Study Group. Blood, 1994, 84, 1361-1392.
89. Morris S. W.; Xue, L.; Ma, Z.; Kinney, M. C. Alk+ CD30+ lymphomas, a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br. J. Haematol., 2001, 113, 275-95.
90. Stein, H.; Foss, H. D.; Durkop, H.; Marafioti, T.; Delsol, G.; Pulford, K.; Pileri, S.; Falini, B. CD30(+) anaplastic large cell lymphoma, a review of its histopathologic, genetic, and clinical features. Blood, 2000, 96, 3681-3695.
91. Falini, B.; Pulford, K.; Pucciarini, A.; Carbone, A.; De Wolf-Peeters, C.; Cordell, J.; Fizzotti, M.; Santucci, A.; Pelicci, P. G.; Pileri, S.; Campo, E.; Ott, G.; Delsol, G.; Mason, D. Y. Lymphomas expressing ALK fusion protein(s) other than NPMALK. Blood, 1999, 94, 3509-3515.
92. Lamant, L.; Gascoyne, R. D.; Duplantier, M. M.; Armstrong, F.; Raghab, A.; Chhanabhai, M.; Rajcan-Separovic, E.; Raghab, J.; Delsol, G.; Espinos, E. Non-muscle myosin heavy chain (MYH9), a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chrom. Cancer, 2003, 37, 427-432.
93. Park, J. P.; Curran, M. J.; Levy, N. B.; Davis, T. H.; Elliott, J. H.; Mohandas, T. K. Diffuse large cell, B-cell type lymphoma with a novel translocation (2, 22)(p23, q11.2). Cancer Genet Cytogenet., 1997, 96, 118-122.
94. Coffin, C. M.; Dehner, L. P.; Meis-Kindblom, J. M. Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma and related lesions, an historical review with differential diagnostic considerations. Semin Diagn. Pathol., 1998, 15, 102-10.
95. Griffin, C. A.; Hawkins, A. L.; Dvorak, C.; Henkle, C.; Ellingham, T.; Perlman, E. J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res., 1999, 59, 2776-2780.
96. Lawrence, B.; Perez-Atayde, A.; Hibbard, M. K.; Rubin, B. P.; Dal Cin, P.; Pinkus, J. L.; Pinkus, G. S.; Xiao, S.; Yi, E. S.; Fletcher, C. D.; Fletcher, J. A. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol., 2000, 157, 377-384.
97. Bridge, J. A.; Kanamori, M.; Ma, Z.; Pickering, D.; Hill, D. A.; Lydiatt, W.; Lui, M. Y.; Colleoni, G. W.; Antonescu, C. R.; Ladanyi, M.; Morris, S. W. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol., 2001, 159, 411-415.
98. Debiec-Rychter, M.; Marynen, P.; Hagemeijer, A.; Pauwels, P. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chrom. Cancer. 2003, 38, 187-190.
99. Hubbard, S. R. Protein tyrosine kinases, autoregulation and smallmolecule inhibition. Curr. Opin. Struct. Biol., 2002, 12, 735-741.
100. Hubbard, S. R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2004, 5, 464-471.
101. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. Embo. J., 1997, 16, 5572-5581.
102. Hubbard, S. R. Autoinhibitory mechanisms in receptor tyrosine kinases. Front, Biosci., 2002, 7, d330-40.
103. Bossi, R. T.; Saccardo, M. B.; Ardini, E.; Menichincheri, M.; Rusconi, L.; Magnaghi, P.; Orsini, P.; Avanzi, N.; Borgia, AL.; Nesi, M.; Bandiera, T.; Fogliatto, G.; Bertrand, J. A. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochem., 2010, 49, 6813-6825.
104. Lee, C. C.; Jia, Y.; Li, N.; Sun, X.; Ng, K.; Ambing, E.; Gao, M. Y.; Hua, S.; Chen, C.; Kim, S.; Michellys, P. Y.; Lesley, S. A.; Harris, J. L.; Spraggon, G. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem. J., 2010, 430, 425-437.
105. Gunby, R. H.; Ahmed, S.; Sottocornola, R.; Gasser, M.; Redaelli, S.; Mologni, L.; Tartari, CJ.; Belloni, V.; Gambacorti-Passerini, C.; Scapozza, L. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis.; inhibitor binding analysis, and homology modeling. J. Med. Chem. 2006, 49, 5759-5768.
106. Tartari, C. J.; Gunby, R. H.; Coluccia, A. M.; Sottocornola, R.; Cimbro, B.; Scapozza, L.; Donella-Deana, A.; Pinna, L. A.; Gambacorti-Passerini, C. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J. Biol. Chem., 2008, 283, 3743-3750.
107. Wang, P.; Wu, F.; Ma, Y.; Li, L.; Lai, R.; Young, L. C. Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry. J. Biol. Chem., 2010, 285, 95-103.
108. Moretti, L.; Tchemin, L.; Scapozza, L. Tyrosine kinase drug discovery, What can be learned from solved crystal structures? Arkivoc (viii). 2006, 38-49.
109. Li, R.; Xue. L.; Zhu, T.; Jiang, Q.; Cui, X.; Yan, Z.; McGee, D.; Wang, J.; Gantla. V. R.; Pickens, J.C.; McGrath, D.; Chucholowski, A.; Morris, S. W.; Webb. T. R. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J. Med. Chem., 2006, 49, 1006-1015.
110. Gregor, V. E.; Liu, Y.; Anikin, A. Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders. CHEMBRIDGE RESEARCH LABORATORIES INC., 2008.
111. Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA, 2007, 104, 270-275.
112. Sausville, E. A.; Arbuck, S. G.; Messmann, R.; Headlee, D.; Bauer, K. S.; Lush, R. M.; Murgo, A.; Figg, W. D.; Lahusen, T.; Jaken, S.; Jing, X.; Roberge, M.; Fuse, E.; Kuwabara, T.; Senderowicz, A. M. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol., 2001, 19, 2319-2333.
113. Wang, Q.; Fan, S.; Eastman, A.; Worland, P. J.; Sausville, E. A.; O'Connor, P. M. UCN-01, a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 1996, 88, 956-965.
114. Christensen, J, G.; Schreck. R.; Burrows. J.; Kuruganti. P.; Chan. E.; Le, P.; Chen, J.; Wang, X.; Ruslim, L.; Blake, R.; Lipson, K. E.; Ramphal, J.; Do, S.; Cui, J. J.; Cherrington, J. M.; Mendel, D. B. A selective small molecule inhibitor of c-Met kinase inhibits c-Metdependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res., 2003, 63, 7345-7355.
115. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell, 2002, 109, 275-282.
116. Gennäs, G. B.; Mologni, L.; Ahmed, S.; Rajaratnam, M.; Lindholm, N.; Viltadi, M.; Gambacorti-Passerini, C.; Scapozza, L.; Yli-Kauhaluoma, J. Design, Synthesis and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. Submitted.
117. Gambacorti-Passerini, C.; Mologni, L.; Scapozza, L.; Ahmed, S.; Goekjian, P.; Gueyrard, D.; Popowycz, F.; Joseph, B.; Schneider, C.; Garcia, P. Alfa-carboline inhibitors of NPM/ALK, RET and BCR-ABL. 2010, WC2010025872.
118. Gambacorti-Passerini, C.; Gunby, R.; Zambon, A.; Scapozza, L.; Ahmed, S.; Goekjian, P.; Gueyrard, D.; Popowycz, F.; Schneider, C. Antiproliferative compounds and therapeutic uses thereof. 2009, WC2009121535.
119. Gunby, R. H.; Sottocornola, R.; Gasser, M.; Scapozza, L.; Gambacorti-Passerini, C. B. Generation and verification of a threedimensional model of the alk kinase domain, alk-a 'supermutant' of Abl. Blood, 2004, 104, 952a.
120. Gunby, R. H.; Tartari, C. J.; Porchia, F.; Donella-Deana, A.; Scapozza, L.; Gambacorti-Passerini, C. An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. Haematologica, 2005, 90, 988-990.
121. Li, R.; Morris, S. W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med, Res, Rev., 2008, 28, 372-412.
122. Gu, L.; Gao, J.; Li, Q.; Zhu, Y. P.; Jia, C.S.; Fu, R.Y.; Chen, Y.; Liao, Q.K.; Ma, Z. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway enhancing G1 cell cycle arrest and apoptosis. Leukemia, 2008, 22, 2091-2096.
123. Marzec, M.; Kasprzycka, M.; Ptasznik, A.; Wlodarski, P.; Zhang, Q.; Odum, N.; Wasik, M.A. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab. Invest., 2005. 85, 1544-1554.
124. Wan, W.; Albom, M.S.; Lu, L.; Quail, M.R.; Becknell, N.C.; Weinberg, L.R.; Reddy, D. R.; Holskin, B.P.; Angeles TS.; Underiner TL.; Meyer SL.; Hudkins RL.; Dorsey BD.; Ator MA.; Ruggeri BA.; Cheng M. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood, 2006, 107, 1617-1623.
125. Christensen, J.G.; Zou, H.Y.; Arango, M.E.; Li, Q.; Lee, J.H.; McDonnell, S.R.; Yamazaki, S.; Alton, G.R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066 a novel inhibitor of anaplastic lymphoma kinase and c-Met in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther., 2007, 6, 3314-3322.
126. Zou, H.Y.; Li, Q.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.J.; Kung, P.P.; Nambu, M.D.; Los, G.; Bender, S.L.; Mroczkowski, B.; Christensen, J.G. An orally available small-molecule inhibitor of c-Met PF-2341066 exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res., 2007, 67, 4408-4417.
127. Kwak, E.L.; Camidge, D.R.; Clark, J.; Shapiro, G.I.; Maki, R.G.; Ratain, M.J.; Solomon, B.; Bang, Y.; Ou, S.; Salgia, R. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor PF-02341066. J. Clin. Oncol. 27, 15s,; 2009 (suppl; abstr 3509). 2009.
128. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Jänne, P.A.; Costa, D.B.; Varella-Garcia, M.; Kim, W.H.; Lynch, T.J.; Fidias, P.; Stubbs, H.; Engelman, J.A.; Sequist, L.V.; Tan, W.; Gandhi, L.; Mino-Kenudson, M.; Wei, G.C.; Shreeve, S.M.; Ratain, M.J.; Settleman, J.; Christensen, J.G.; Haber, D.A.; Wilner, K.; Salgia, R.; Shapiro, G.I.; Clark, J.W.; Iafrate, A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med., 2010, 363(18): 1693-703. Erratum in: N. Engl. J. Med., 2011, 364(6), 588.
129. Butrynski, J.E.; D'Adamo, D.R.; Hornick, J.L.; DalCin, P.; Antonescu, C.R.; Jhanwar, S.C.; Ladanyi, M.; Capelletti, M.; Rodig, S.J.; Ramaiya, N.; Kwak, E.L.; Clark, J.W.; Wilner, K.D.; Christensen, J.G.; Jänne, P.A.; Maki, R.G.; Demetri, G.D.; Shapiro, G.I. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med., 2010, 363(18), 1727-33.
130. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med., 2011, 364(8), 775-6.
131. Wood, A.C.; Laudenslager, M.; Haglund, E.A.; Attiyeh, E.F.; Pawel, B.R.; Courtright, J.; Plegaria, J.; Christensen, J.G.; Maris, J. M.; Mosse, Y.P. Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066. J. Clin. Oncol., 27, 15s, 2009 (suppl, abstr 10008b). 2009.
132. McDermott, U.; Iafrate, A.J.; Gray, N.S.; Shioda, T.; Classon, M.; Maheswaran, S.; Zhou, W.; Choi, H.G.; Smith, S.L.; Dowell, L.; Ulkus, L.E.; Kuhlmann, G.; Greninger, P.; Christensen, J.G.; Haber, D.A.; Settleman, J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res., 2008, 68, 3389-3395.
133. Ardini, E.; Menichincheri, M.; De Ponti, C.; Amboldi, N.; Saccardo, M.B.; Texido, G.; Russo, M.; Orsini, P.; Bandiera, T.; Borgia, A.L.; Isacchi, A.; Pesenti, E.; Colotta, F.; Magnaghi, P.; Galvani, A.; Medical, N. Abstract A243, Characterization of NMS-E628.; a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer. Mol. Targets Ther., 8, December 10. 2009 ed. Boston.; M.A. American Association for Cancer Research; 2009.
134. Zhang, S.; Wang, F.; Keats, J.; Ning, Y.; Dardwell, S.D.; Moran, L.; Mohemmad, Q.K.; Ye, E.; Anjum, R.; Wang, Y.; Zhu, X.; Miret, J.J.; Dalgarno, D.; Narasimhan, N.I.; Clackson, T.; Shakespeare, W.C.; Rivera, V.M. AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066. In, ARIAD Pharmaceuticals I.; Cambridge, MA, USA, ed. AACR 2010. Washington DC, 2010.
135. Rivera, V.M.; Anjum, R.; Wang, F.; Zhang, S.; Keats, J.; Ning, Y.; Wardwell, S.D.; Moran, L.; Ye, E.; Chun, D.Y.; Mohemmad, Q.K.; Liu, S.; Huang, W.S.; Wang, Y.; Thomas, M.; Li, F.; Qi, J.; Miret, J.J.; Iuliucci, J.D.; Dalgarno, D.; Narasimhan, N.I.; Clackson, T.; Shakespeare, W.C. Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK). In, ARIAD Pharmaceuticals I, Cambridge, MA, USA, ed. AACR 2010. Washington DC; 2010.